ISUPREL
LOE ApproachingNDARECTAL, SUBLINGUALTABLET
Approved
Feb 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISUPREL is a legacy small-molecule tablet approved in 1948, administered via rectal or sublingual routes. The drug's specific mechanism of action and therapeutic indications are not documented in current data, suggesting it may be a historical formulation with limited contemporary clinical use. This product represents an older generation of pharmaceutical development with potential heritage value in specific patient populations.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial momentum; career opportunities likely limited to maintenance and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ISUPREL offers limited career growth, with no current open positions and minimal commercial momentum. Roles focus on regulatory compliance, managed decline, and transition management rather than innovation or expansion.
Regulatory Affairs SpecialistProduct Manager (Maintenance)
Worked on ISUPREL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.